Analytical Data
-
Gene name
Defb19
- Application
-
Alternative Names
BD-19;mBD-19;Defensin, beta 19;Testis-specific beta-defensin-like protein
-
Species
Mouse
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8K3I8
-
Expression Region
20-83aa
-
Molecular Weight
15.0 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Defb19, a member of the defensin family, plays a crucial role in the innate immune response, particularly in the defense against pathogens. Identified predominantly in mice, Defb19 is known for its antimicrobial properties, exhibiting effects against a wide array of bacteria, fungi, and viruses. Research on Defb19 has gained momentum due to its potential therapeutic applications in managing infectious diseases and enhancing innate immunity. As the global concerns regarding antibiotic resistance escalate, understanding the mechanisms underlying the action of defensins like Defb19 could provide valuable insights into novel antimicrobial strategies. Additionally, the ability of Defb19 to modulate immune responses positions it as an attractive candidate for vaccine adjuvants and immunotherapy. Recent studies have employed advanced techniques such as recombinant protein production and structural biology to elucidate the functional properties of Defb19, aiming to harness its potential in clinical applications. The exploration of Defb19’s molecular mechanisms also contributes to the broader understanding of host-pathogen interactions and immune regulation, marking it as a significant focus in immunology and microbiology research. In summary, the study of Defb19 recombinant protein not only highlights its importance in innate immunity but also underscores the need for innovative solutions in combating infectious diseases in an era of rising antimicrobial resistance.
